Clinical Trials Logo

Filter by:
NCT ID: NCT03560908 Withdrawn - Relapsed AML Clinical Trials

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Start date: July 1, 2018
Phase: Phase 1
Study type: Interventional

In this multi-center, open-label, no control,prospective clinical trial, a total of 30 relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients will be enrolled. Dasatinib 70 mg twice a day will be administrated for two weeks from day 1 of re-induction chemotherapy. The purpose of current study is to determine the clinical efficacy and tolerability of combination therapy of dasatinib with multi-agent chemotherapy in relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation.

NCT ID: NCT03554395 Withdrawn - Clinical trials for Advanced Gastric Cancer

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer

Start date: April 5, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced gastric cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for gastric cancer.

NCT ID: NCT03540199 Withdrawn - Clinical trials for Advanced Kidney Cancer

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Start date: April 10, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced kidney cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for kidney cancer.

NCT ID: NCT03527498 Withdrawn - Cerebral Infarction Clinical Trials

Evaluation of Long-term Neurodevelopment in Neonatal Encephalopathy by Infant Treadmill

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

There is no international application of infant running stimulation system to evaluate the brain injury in children with various stages of nerve and motor development in a large sample of studies. The study of neonatal brain injury is only limited to intraventricular hemorrhage(IVH),periventricular leukomalacia(PVL), Down's syndrome(DS), premature birth of these four conditions, and the number of samples in the single digits, there is no representative of the disease population. Therefore, from the newborn to the infant development of the critical period, the investigator will refer to the previous treadmill parameters set on the research results, optimize the application of neonatal treadmill. The study hypothesized that neonatal treadmill stimulation with brain-injured children could improve his / her staggered gait characteristics and long-term nerve development through large sample data. It is important to preserve and analyze the gait characteristics and the changes of nerve development in every stage of growth and development of neonates with brain injury so as to provide clinical evidence for rehabilitation intervention. It is of great significance to judge whether this technique can be used in the early stage of brain injury in neonates.

NCT ID: NCT03526367 Withdrawn - Clinical trials for ST Elevation Myocardial Infarction

A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI

TRACK-AMI
Start date: February 20, 2019
Phase: Phase 4
Study type: Interventional

The CIAKI,as the third complication of PCI, was associated with adverse cardiac events after procedure. Moreover, because the rate of periprocedure hydration is inadequate in STEMI patients before primary PCI, the incidence of CIAKI is higher significantly in these patients. The cardiovascular pleiotropic effects of statins in addition to lipid have been widely concerned. The previous studies demonstrated usage of statin in periprocedure could decrease the risk of CIAKI. Compared with hydration, the usage of statin to prevention CIAKI show the advantages in clinical practice, for example,there is no need to consider the cardiac function.The optimal strategies for preventting CIAKI in STEMI patients undergoing primary PCI needed further studies to explore. What's more, whether a synergistic effect of hydration and statin or not is unknown.

NCT ID: NCT03524274 Withdrawn - Clinical trials for Advanced Colorectal Cancer

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer

Start date: April 5, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced colorectal cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for colorectal cancer.

NCT ID: NCT03524261 Withdrawn - Clinical trials for Advanced Breast Cancer

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced breast cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for breast cancer.

NCT ID: NCT03521128 Withdrawn - Hydrosalpinx Clinical Trials

Comparing Radiological Tubal Blockage Versus Laparoscopic Salpingectomy in Infertile Women With Hydrosalpinx During in Vitro Fertilization Treatment

Start date: May 5, 2018
Phase: N/A
Study type: Interventional

Hydrosalpinx (HX) has a detrimental effect on the rates of implantation, pregnancy, live delivery, and early pregnancy loss during in vitro fertilization (IVF). The effectiveness of radiological tubal blockage has not been compared with the standard treatment of laparoscopic salpingectomy in randomized trials. The investigators aim in this randomized trial to compare the live birth rate of radiological tubal blockage versus laparoscopic salpingectomy in infertility women with HX prior to frozen-thawed embryo transfer (FET). Eligible women will be recruited and randomized into one of the following two groups: (1) the radiological tubal blockage group and (2) the laparoscopic salpingectomy group. The primary outcome is the live birth rate.

NCT ID: NCT03516851 Withdrawn - Moyamoya Disease Clinical Trials

Precision Bypass in Patients With Moyamoya Disease

PBM
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

Extracranial-intracranial arterial bypass, including anastomosis of the superficial temporal artery to the middle cerebral artery and indirect bypass, can help prevent further ischaemic attacks in patients with Moyamoya disease (MMD). However, there is no established standard for the selection of the recipient vessels. In most situations, surgeons choose the recipient vessels with their own experiences. Intraoperative Indocyanine green (ICG) angiography using Flow800 software and multimodal neuronavigation can be used to assess the real-time cerebral blood flow velocity and perfusion of local brain tissue for better selection of the recipient vessels. Thus the aim of this study is to to determine whether direct bypass surgery combined with multimodal neuronavigation is superior to traditional direct bypass procedure alone in adult ischemic MMD patients.

NCT ID: NCT03509298 Withdrawn - Clinical trials for Advanced Pancreatic Cancer

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer

Start date: April 12, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced pancreatic cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for pancreatic cancer.